Palo Alto, CANCT06005038Now EnrollingIRB Ready

Mild Cognitive Impairment Clinical Trial in Palo Alto, CA

Access cutting-edge mild cognitive impairment treatment through this phase 1 clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.

Sponsored by Stanford University

Quick Self-Assessment

See if you qualify for this Palo Alto location

Preparing your pre-screening questions…

Expert Care in Palo Alto

Access mild cognitive impairment specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mild cognitive impairment treatment provided free

Apply for This Palo Alto Location

Check if you qualify for this mild cognitive impairment clinical trial in Palo Alto, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palo Alto

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palo Alto site if eligible
  4. 4Begin participation

About This Mild Cognitive Impairment Study in Palo Alto

(JUSTIFICATION: This is the R33 stage of an NIH funded R21/R33 study. R21 stage (IRB-61727) was focused on intervention development; R33 stage will focus on pilot testing the effect of the intervention. The R21 phase was not considered a NIH defined clinical trial; R33 will be considered a NIH defined clinical trial) The purpose is to develop and test the effect of a "personalized" computer-based cognitive training program. The personalized program tailors the difficulty of the training tasks using a participant's biofeedback (i.e., heart rate) and cognitive performance. Such a personalization will ensure that the participant can perform at his/her ideal training capacity. Participants will be randomized into one of 2 groups and each group will play a different version of computerized training game and have ECG collected to allow subject blinding.

Sponsor: Stanford University

Who Can Participate

Inclusion Criteria

criteria related to defining "mild cognitive impairment": a. Presence of memory complaint; b. Rey Auditory Verbal Learning Test delayed recall (for memory) \< 59% of age-adjusted norm; c. Montreal Cognitive Assessment (for global cognition) ranged 18 and 27; d. Functional Assessment Questionnaire (for activities of daily living) \< 20.
intact score for San Diego Brief Assessment of Capacity to Consent (UBACC).
if a participant is on AD medication (i.e., memantine, cholinesterase inhibitors, amyloid antibodies), antidepressants, anxiolytics, or vascular risk or diseases related medications (e.g., beta-blocker), the dose should be stable for 3 months prior to recruitment.
read and understand English
adequate visual and hearing acuity for testing by self-report,
community-dwelling (including independent living).

Exclusion Criteria

current enrollment in another cognitive improvement study;
uncontrollable major depression;
major cerebrovascular and cardiovascular diseases (e.g., congestive heart failure, pacemaker, prior myocardial infarction);
having an active legal guardian (indicating impaired capacity for decision making);
currently pregnant
3T MRI contraindication
Neurological conditions: Neurodegenerative disease diagnosis such as Parkinson's, Alzheimers, dementia, multiple sclerosis. Of note, other neurological conditions/injury such as stroke, seizures, traumatic brain injury, will be evaluated for inclusion/exclusion on a case-by-case basis based on event recency, severity, and recovery.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palo Alto?

Yes, this clinical trial (NCT06005038) has an active research site in Palo Alto, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mild Cognitive Impairment Treatment Options in Palo Alto, CA

If you're searching for mild cognitive impairment treatment options in Palo Alto, CA, this clinical trial (NCT06005038) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palo Alto research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced mild cognitive impairment specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mild cognitive impairment clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Palo Alto, CA

See all heart attack clinical trials recruiting in Palo Alto — not just this study.

Browse Heart Attack Trials in Palo Alto →

Ready to Join in Palo Alto?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palo Alto, CA